ISPOR - Cost-Minimization Analysis (CMA) of Canagliflozin Compared to Glimepiride and Sitagliptin as Dual Therapy in Combination with Metformin

Full Text

Cost-Minimization Analysis (CMA) of Canagliflozin Compared to Glimepiride and Sitagliptin as Dual Therapy in Combination with Metformin

Abstract

Authors

R Ravasio P Pisarra M Comaschi

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now